Pfizer: third approval for Xtanti in prostate cancer
(CercleFinance.com) - US regulators have approved Pfizer's Xtandi for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC), a form of prostate cancer that has spread to other parts of the body.
With this approval, Xtandi is now the first and only pill approved by the FDA in three distinct types of advanced prostate cancer - non-metastatic and metastatic castration-resistant prostate cancer (CRPC) and mCSPC.
This approval means that doctors can now offer Xtandi to men earlier in their advanced prostate cancer treatment.
Data showed that the use of Xtandi - which is being jointly developed with Japan's Astellas - plus androgen deprivation therapy (ADT) significantly reduced the risk of progression or death by 61% compared to placebo.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
With this approval, Xtandi is now the first and only pill approved by the FDA in three distinct types of advanced prostate cancer - non-metastatic and metastatic castration-resistant prostate cancer (CRPC) and mCSPC.
This approval means that doctors can now offer Xtandi to men earlier in their advanced prostate cancer treatment.
Data showed that the use of Xtandi - which is being jointly developed with Japan's Astellas - plus androgen deprivation therapy (ADT) significantly reduced the risk of progression or death by 61% compared to placebo.
Copyright (c) 2019 CercleFinance.com. All rights reserved.